Nicotine orally-dissolving film - NAL Pharma
Alternative Names: NAL 2762Latest Information Update: 24 Mar 2025
At a glance
- Originator NAL Pharma
- Class Alkaloids; Analgesics; Drug withdrawal therapies; Nicotine replacement therapy; Pyridines; Small molecules
- Mechanism of Action Nicotinic receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Clinical Phase Unknown Smoking withdrawal
Most Recent Events
- 24 Mar 2025 Nicotine orally-dissolving film is still in clinical trials for smoking-withdrawal (Sublingual, Film) (NAL Pharma pipeline, March 2025)
- 28 May 2024 No recent reports of development identified for clinical-Phase-Unknown development in Smoking-withdrawal in Unknown (Sublingual, Film)
- 26 May 2022 Nicotine orally-dissolving film is still in clinical trials for smoking-withdrawal (NAL Pharma pipeline, May 2022)